MedTrace Logo

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

NCT04451837 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-07-16

No results posted yet for this study

Summary

Current anti-diabetic treatment fails to stop the progressive course of the disease. Recent studies have revealed a surprisingly high variability in the diabetic phenotype. The investigators propose that anti-diabetic treatment should ideally target the underlying pathophysiology of each individual patient. The investigators will therefore test whether the effect of two approved anti-diabetic drugs differs between individuals at different ends of the pathophysiological spectrum: 1) patients with poor insulin secretion, here termed SIDD and 2) patients with high insulin resistance, here termed SIRD. The study may open up a new avenue for more precise treatment of diabetic patients that would be of immediate clinical relevance.

Conditions

  • Type2 Diabetes

Interventions

DRUG

Semaglutide

Ozempic s.c. once weekly for 6 months

DRUG

Dapagliflozin

Forxiga 10 mg p.o. once daily for 6 months

Sponsors & Collaborators

  • Göteborg University

    collaborator OTHER

  • Region Skane

    lead OTHER

Principal Investigators

  • Anders Rosengren · Region Skåne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2021-12-15
Completion
2026-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04451837 on ClinicalTrials.gov